EXPRS2 — ExpreS2ion Biotech Holding AB Share News
0.000.00%
Last trade - 00:00- SEK24.46m
- -SEK8.46m
- SEK12.21m
Brief: ExpreS2ion Biotech Holding Q1 Oper Income Down At SEK 1.9 Mln
Brief: ExpreS2ion Updates On Its Pipeline Outlook, Including For Covid-19 And HER2 Breast Cancer Projects
Brief: ExpreS2ion Biotech: Approval And Initiation Of COVID-19 Clinical Phase I/II Study For The ABNCoV2 Vaccine
Brief: Expres2ion Q4 Loss After Financial Items Widens To SEK 18.8 Mln
Brief: ExpreS2ion And University Of Bologna Announce Research Collaboration
Brief: Expres2ion Carries Out New Share Issue For Loan Conversion
Brief: Expres2ion Q3 Pre-Tax Loss Widens To SEK 5.5 Million
Brief: ExpreS2ion: Successful Manufacturing Of cVLP COVID-19 Vaccine
Brief: Expres2ion's Rights Issue Oversubscribed
Brief: Expres2ion And Attana Have Signed A Development And Supply Agreement
Brief: Expres2ion: Up To SEK 216 Million Capital Raise Through Fully Guaranteed Rights Issue
Brief: Expres2ion Biotech Q2 Loss After Financial Items Widens To SEK 5.0 MILLION
Brief: Expres2ion UpdateS On Expectations To COVID-19 Vaccine Program
Brief: ExpreS2ion Appoints New CFO
Brief: ExpreS2ion Provides Update On Development Of Breast Cancer Vaccine Candidate AV001
Brief: ExpreS2ion's Joint Venture AdaptVac Signs Final License Agreement With Bavarian Nordic On COVID-19 Vaccine
Brief: Bavarian Nordic And AdaptVac Sign Final License Agreement On Covid-19 Vaccine
Brief: ExpreS2ion Biotech Holding: Proof-Of-Concept For Cross-Strain Protective Flu CVLP Vaccine Strengthens Confidence In Coronavirus Vaccine
Brief: Expres2ion Biotech Holding Updates On Negotiations With Bavarian Nordic